The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group

We grouped 162 patients wtih advanced, diffuse histiocytic lymphoma (DHL) into various morphological subtypes to ascertain whether there were any significant differences in survival among them. These patients were staged and treated from 1972 to 1977 according to the protocols of the Southwest Oncology Group. Of the 159 patients on whom a consensus on the diagnosis was reached, 115 were classified morphologically as having large non-cleaved, 26 as B-immunoblastic, 9 as large cleaved, and 6 as T-immunoblastic. The 3 remaining patients did not fit any of these subtypes, but each had a single prominent nucleolus in most tumor cells (“prominent nucleolus” type). Morphological subdivision of DHL did not identify any subgroup of patients with a significantly longer survival, but clinical parameters such as stage, symptoms, and type of treatment significantly influenced survival times.

Download Full-text

The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group

Blood ◽

10.1182/blood.v60.5.1068.1068 ◽

1982 ◽

Vol 60 (5) ◽

pp. 1068-1074 ◽

Cited By ~ 31

Author(s):

BN Nathwani ◽

DO Dixon ◽

SE Jones ◽

RJ Hartsock ◽

JW Rebuck ◽

...

Keyword(s):

Tumor Cells ◽

Clinical Significance ◽

Clinical Parameters ◽

Oncology Group ◽

Survival Times ◽

Southwest Oncology Group ◽

Histiocytic Lymphoma ◽

Diffuse Histiocytic Lymphoma ◽

Prominent Nucleolus

Abstract We grouped 162 patients wtih advanced, diffuse histiocytic lymphoma (DHL) into various morphological subtypes to ascertain whether there were any significant differences in survival among them. These patients were staged and treated from 1972 to 1977 according to the protocols of the Southwest Oncology Group. Of the 159 patients on whom a consensus on the diagnosis was reached, 115 were classified morphologically as having large non-cleaved, 26 as B-immunoblastic, 9 as large cleaved, and 6 as T-immunoblastic. The 3 remaining patients did not fit any of these subtypes, but each had a single prominent nucleolus in most tumor cells (“prominent nucleolus” type). Morphological subdivision of DHL did not identify any subgroup of patients with a significantly longer survival, but clinical parameters such as stage, symptoms, and type of treatment significantly influenced survival times.

Download Full-text

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience.

Journal of Clinical Oncology ◽

10.1200/jco.1986.4.3.295 ◽

1986 ◽

Vol 4 (3) ◽

pp. 295-305 ◽

Cited By ~ 246

Author(s):

D O Dixon ◽

B Neilan ◽

S E Jones ◽

D A Lipschitz ◽

T P Miller ◽

...

Keyword(s):

Dose Reduction ◽

Initial Dose ◽

Treatment Guidelines ◽

Large Cell ◽

Age Group ◽

Oncology Group ◽

Younger Patients ◽

Southwest Oncology Group ◽

Full Dose ◽

Histiocytic Lymphoma

To study the influence of chronologic age on treatment outcome in patients with advanced, diffuse large-cell (histiocytic) lymphoma (DHL), we reviewed the results of two recent Southwest Oncology Group (SWOG) clinical trials. From 1974 to 1982, members entered 307 eligible patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without bleomycin, and CHOP with or without immunotherapy using BCG, levamisole, or both. Complete response (CR) rates declined progressively with advancing age: 65% in those under 40, 60% in the 40 to 54 age group, 55% in the 55 to 64 age group, and 37% in those 65 and older (P = .001). Likewise, survival decreased significantly in older patients: medians were 101 +, 52, 34, and 16 months, respectively (P less than .001). Treatment guidelines included an initial dose reduction of 50% for patients aged 65 or older and for younger patients with bone marrow compromise. Despite protocol specifications, 23 of 81 patients aged 65 or older received initial full-dose therapy. When these patients were compared with younger patients on whom full-dose chemotherapy was started, survival curves, but not CR rates, were still significantly different. There were no significant differences in duration of CR or frequency of treatment complications. These data suggest that older age is associated with a worse prognosis in advanced DHL. Moreover, the initial dose reduction for patients aged 65 or older may have contributed to their inferior outcomes.

Download Full-text

273: Timing of Recurrence and Outcomes Following Induction BCG for High Risk TA, T1 Bladder Cancer - A Southwest Oncology Group Trial

The Journal of Urology ◽

10.1016/s0022-5347(18)37535-9 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 72-72

Author(s):

Seth P. Lerner ◽

Cathy Tangen ◽

Heidi Sucharew ◽

David P. Wood ◽

E. David Crawford

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Oncology Group ◽

Southwest Oncology Group ◽

Group Trial

Download Full-text

P34.02 Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells From Patients With Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.01.693 ◽

2021 ◽

Vol 16 (3) ◽

pp. S415-S416

Author(s):

Y. Cheng ◽

T. Wang ◽

R. Li ◽

X. Lv ◽

L. Yuan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Clinical Significance ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung

Download Full-text

Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database

Journal of Clinical Oncology ◽

10.1200/jco.2008.18.9035 ◽

2009 ◽

Vol 27 (5) ◽

pp. 733-739 ◽

Cited By ~ 81

Author(s):

Deborah T. Blumenthal ◽

Minhee Won ◽

Minesh P. Mehta ◽

Walter J. Curran ◽

Luis Souhami ◽

...

Keyword(s):

Multivariate Analysis ◽

Radiation Therapy ◽

Treatment Regimen ◽

Radiation Therapy Oncology Group ◽

Secondary Analysis ◽

Time Interval ◽

Oncology Group ◽

Survival Times ◽

Short Delay ◽

Time To Initiation

Purpose To analyze the Radiation Therapy Oncology Group (RTOG) database of patients with glioblastoma and appraise whether outcome was influenced by time to initiation of radiation therapy (RT). Patients and Methods From 1974 through 2003, adult patients with histologically confirmed supratentorial glioblastoma were enrolled onto 16 RTOG studies. Of 3,052 enrolled patients, 197 patients (6%) were either initially rendered ineligible or had insufficient chronologic data, leaving a cohort of 2,855 patients for the present analysis. We selected four patient groups based on the interval from surgery to the start of RT: ≤ 2 weeks, 2 to 3 weeks, 3 to 4 weeks, more than 4 weeks to the protocol eligibility limit of 6 weeks. Survival times were estimated by the Kaplan-Meier method. Multivariate analysis incorporated variables of time interval, recursive partitioning analysis (RPA) class, and treatment regimen. Results No decrement in survival could be identified with increasing time to initiation of RT. Among our four temporal groupings, median survival time was unexpectedly and significantly greater in the group with the longest interval (> 4 weeks) than in those with the shortest delay (≤ 2 weeks): respectively, 12.5 months versus 9.2 months (P < .0001). On multivariate analysis, with overall survival as the end point, time interval more than 4 weeks and lower RPA class were both significant predictors of improved outcome. Treatment regimen was not a significant factor. Conclusion There is no evident reduction in survival by delaying initiation of RT within the relatively narrow constraint of 6 weeks. An unanticipated yet significantly superior outcome was identified for patients for whom RT was delayed beyond 4 weeks from surgery.

Download Full-text